MicroRNA profiling in the serums of SCA3/MJD patients
MicroRNA profiling in the serums of SCA3/MJD patients
复制标题
DOI：
10.3109/00207454.2013.827679
复制
发表时间：
2014-02-01
影响因子：
2.2
通讯作者：
Jiang, Hong
中科院分区：
文献类型：
--
作者：
Shi, Yuting;Huang, Fengzhen;Jiang, Hong
脊髓小脑性共济失调3型/马查多-约瑟夫病（SCA 3/MJD）是我国最常见的脊髓小脑性共济失调类型。然而，SCA 3/MJD的发病机制尚不清楚。MicroRNA（miRNAs）已被反复证明以生物稳定的形式存在于人外周血清中，并已被证明是其他神经退行性疾病的有用生物标志物。然而，没有SCA 3/MJD患者的研究评估了调节性miRNA的特异性变化。因此，我们系统地使用miRCURYTM LNA Array，然后进行定量实时聚合酶链反应验证，以获得SCA 3/MJD患者血清中的miRNA表达水平。我们的结果表明，miR-25、miR-125 b、miR-29 a和miR-34 b可能是SCA 3/MJD的潜在生物标志物，并可用于进一步研究SCA 3/MJD的发病机制和药物开发。
Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is the most common type of spinocerebellar ataxia in China. However, the pathogenesis of SCA3/MJD is still unknown. MicroRNAs (miRNAs) have been repeatedly demonstrated to exist in human peripheral serum in a bio-stable form and have been shown to be useful biomarkers for other neurodegenerative disorders. However, no study of SCA3/MJD patients has assessed specific changes in regulatory miRNAs. Therefore, we systematically used the miRCURYTM LNA Array, followed by quantitative real-time polymerase chain reaction validation, to access miRNA expression levels in the serums from SCA3/MJD patients. Our results show that miR-25, miR-125b, miR-29a, and miR-34b could be potential biomarkers for SCA3/MJD and could be used to further investigate the pathogenesis of SCA3/MJD and drug development.